Figure 10 ) were orally treated with mesalamine for 2 weeks; 24 hours after the last administration of mesalamine, the mice were treated with 3% DSS to induce colitis. ( B ) Body weight changes in mice after administration of DSS (n = 7 mice per group). ( C ) Stool score changes in mice after administration of DSS (n = 7 mice per group). ( D ) Colon length in mice after administration of DSS (n = 7 mice per group). ( E ) Colon histopathology. Representative pictures ( left ) and quantitative data ( right ). Scale bar indicates 100 μm (n = 3 per group). (F) TNF-α, IL1β, IL6, MPO, and HO-1 mRNA levels in the colon after administration of DSS were analyzed by Q-PCR (n = 7 mice per group). Error bars represent mean ± SEM. * P < .05, ** P < .01. 5-ASA, mesalamine. " width="100%" height="100%">
Journal: Cellular and Molecular Gastroenterology and Hepatology
Article Title: Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon Receptor
doi: 10.1016/j.jcmgh.2017.03.010
Figure Lengend Snippet: Mice pretreated with mesalamine acquire the resistance to DSS-induced colitis. ( A ) Experimental protocol. WT or AhR -/- mice (see Figure 10 ) were orally treated with mesalamine for 2 weeks; 24 hours after the last administration of mesalamine, the mice were treated with 3% DSS to induce colitis. ( B ) Body weight changes in mice after administration of DSS (n = 7 mice per group). ( C ) Stool score changes in mice after administration of DSS (n = 7 mice per group). ( D ) Colon length in mice after administration of DSS (n = 7 mice per group). ( E ) Colon histopathology. Representative pictures ( left ) and quantitative data ( right ). Scale bar indicates 100 μm (n = 3 per group). (F) TNF-α, IL1β, IL6, MPO, and HO-1 mRNA levels in the colon after administration of DSS were analyzed by Q-PCR (n = 7 mice per group). Error bars represent mean ± SEM. * P < .05, ** P < .01. 5-ASA, mesalamine.
Article Snippet: For Th1 or Th17 cell polarization, naive CD4 + T cells were stimulated with immobilized anti-CD3 mAb and soluble anti-CD28 mAb for Th0; with recombinant mouse IL12 (10 ng/mL, R&D Systems) plus anti-IL4 mAb (10 μg/mL, clone11B11, eBioscience) for Th1; and with human TGF-β1, mouse IL6 (30 ng/mL, R&D Systems), anti-IL4 mAb, and anti-IFN-γ mAb (10 μg/mL, cloneXMG1.2, eBioscience) for Th17, with the indicated concentration of mesalamine, for 3 days.
Techniques: Histopathology